Transplantation Therapies

Abstract

Embodiments of the present invention are directed to methods and dosage forms for treating inflammation and rejection in transplantation injuries with Bryostatin-1, Bryostatin-1 analogs and pharmaceutically acceptable salts thereof.

1 - 42 . (canceled) 
     
     
         43 . A dosage form for treating transplantation injury comprising an effective amount of Bryostatin-1, Bryostatin-1 analog or a pharmaceutically acceptable salt thereof to reduce or prevent induced neutrophil trans endothelial migration wherein said dosage form is a sterile, isotonically acceptable and pH acceptable, nontoxic aqueous solution for perfusion to a transplantation organ for administration to a human or animal in need thereof; wherein said dosage form comprises saturated polyalkylene glycol glyceride. 
     
     
         44 . The dosage form of  claim 43  wherein said polyalkylene glycol glyceride is a mixture of polyalkylene esters of one or more eight carbons to eighteen carbons saturated fatty acids with glycerol. 
     
     
         45 . The dosage form of  claim 44  wherein said polyalkylene glycol is a polyethylene glycol having a molecular weight of 1000 to 2000 daltons. 
     
     
         46 . The dosage form of  claim 46  wherein said polyalkylene glycol is a polyethylene glycol having a molecular eight of 1400 to 1600 daltons. 
     
     
         47 . The dosage form of  claim 43  wherein said Bryostatin-1, Bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said pharmaceutical formulation in an amount of 0.00005 to 0.5% by weight. 
     
     
         48 . The dosage form of  claim 43  wherein said Bryostatin-1, Bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said pharmaceutical formulation in an amount of 0.001 to 0.1% by weight. 
     
     
         49 . The dosage form of  claim 43  wherein said Bryostatin-1, Bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said pharmaceutical parenteral formulation as a dispersion in water having a concentration of 0.01 to 0.1% by weight. 
     
     
         50 . The dosage form of  claim 43  wherein said Bryostatin-1, Bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said pharmaceutical parenteral formulation as a dispersion in water having a concentration of 0.0005 to 0.5% by weight. 
     
     
         51 . The dosage form of  claim 43  wherein said effective amount is a plasma concentration is about 10 −7  M.